% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

hankmanoo 8 posts  |  Last Activity: Jun 23, 2016 11:46 PM Member since: Apr 16, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • hankmanoo hankmanoo Jun 23, 2016 11:46 PM Flag

    Except for gold!

  • What do you think the effect of Brexit will be on CLF if EXIT wins?

  • Reply to

    Part 1: Why is CUR so low?

    by hankmanoo Jun 16, 2016 8:59 AM
    hankmanoo hankmanoo Jun 16, 2016 9:50 AM Flag

    There were more parts that I posted with the rest of the quotes but (terrible) Yahoo gobbled them up and did not allow the posts.

  • I used to hold some CUR in my portfolio but sold it a long time ago. I have now returned to have another look at CUR and am puzzled. I find the share price much much lower, the CUR website still talks about a seemingly good result for PII in the 566 trial whereas all the commentary Feuerstein and others see a failure with a acceleration of the disease in many of the patients whereas the CUR website says explicitly that there was no acceleration. I quote both below and note that the market does not seem to believe CUR – witness the low SP. Could someone explain to me what is happening here? Here are the quotes:

    From the current CUR website:
    Neuralstem ALS Trials
    Neuralstem concluded final surgeries in the company’s NSI-566/ALS Phase II trial, primarily evaluating safety, in July 2014. After a six month patient follow-up period, this phase of the study concluded in the first quarter of 2015. A larger, controlled, registration directed NSI-566/ALS clinical trial is expected to commence in 2016.

    Nine-month Phase II and combined Phase I/II NSI-566 ALS data was presented at the American Neurological Association Annual Meeting by Dr. Feldman, in September 2015. The data showed that the intraspinal transplantation of the cells was safe and well-tolerated throughout the escalating doses, reaching a maximum tolerated dose of 16 million cells via 20 bilateral injections. Further, there appeared to be no acceleration in disease progression due to the therapeutic intervention.

    Researchers calculated a 95% confidence limit around the slopes of decline of ALSFRSr scores, forced vital capacity (FVC) and grip strength of the ProAct historical database subjects, and evaluated if trial subjects fell within or outside those limits. 73% of Phase II patients, and 79% of combined Phase I and II patients, fell above the upper confidence limit of the ALSFRSr score. 50% of Phase I and II combined, and 40% of Phase II patients' forced vital capacity percent predicted fell above the upper

  • What is the current status of the bankruptcy in Canada? Has anything happened in the last few months?

  • Reply to

    Interesting slide from ASCO

    by james_5050 Jun 6, 2016 12:34 PM
    hankmanoo hankmanoo Jun 6, 2016 7:36 PM Flag

    Where can I find this interesting slide from ASCO? Can you supply a link?

  • Reply to


    by hankmanoo Jun 3, 2016 10:43 AM
    hankmanoo hankmanoo Jun 3, 2016 11:40 AM Flag

    Yup, I saw the NR on Fardis, but could not imagine she was worth about $2.50 a share increase - that is about a 50% increase in share value - so I was looking for some other piece of info to explain it. So I am still puzzled?

  • hankmanoo by hankmanoo Jun 3, 2016 10:43 AM Flag

    I held some LBIO some time ago and check in to see how it is doing every once in a while as I still think it may have some possibility. Today however i am puzzled and probably missing some piece of info. could someone please striagten me out or fill me in.

    While the news today reads ablout a large about $100M financing at about $4.75 per share, nevertheless todays price on Yahoo is at $7.10 - up $1.08 - as I write. That is a huge mismatch as usually the market price goes to about the cost of the new financing unless there is some very specific great news. what am I missing????

0.4202+0.0054(+1.30%)Aug 26 4:00 PMEDT